万邦德(002082) - 2025 Q4 - 年度业绩

Financial Performance - Total revenue for 2025 was CNY 114,471.84 million, a decrease of 20.69% compared to CNY 144,336.52 million in the previous year[4] - Operating profit fell to CNY -17,232.43 million, a decline of 386.55% from CNY 6,013.69 million year-on-year[4] - Net profit attributable to shareholders was CNY -19,877.72 million, down 458.54% from CNY 5,544.1 million in the previous year[4] - Basic earnings per share decreased to CNY -0.32, a drop of 455.56% compared to CNY 0.09 in the previous year[4] - The company’s net assets attributable to shareholders decreased by 6.85% to CNY 248,412.71 million from CNY 266,680.43 million[4] - The company’s weighted average return on equity was -7.71%, down from 2.08% in the previous year[4] Strategic Transition - The company is transitioning from generic drugs to innovative drugs, increasing R&D investment significantly[5] - The company faced intensified market competition and price declines due to national drug procurement policies, impacting profitability[5] - The relocation of the polymer product manufacturing facility affected the production and market supply of medical device products[5] Asset Management - Total assets increased by 1.88% to CNY 440,872.81 million from CNY 432,739.71 million at the beginning of the period[4]